Delivering on the Promise of Cancer Research
F. Stephen Hodi, MD, Director of the Center for Immuno-Oncology spoke at our Joint Visiting Committee Symposium and discussed how researchers are engaging a patient’s own immune system to fight their cancer. This less toxic treatment has shown great promise in melanoma and other cancers.

Delivering on the Promise of Precision Medicine
DF/BWCC now creates a precise "tumor profile" of genomic changes that helps physicians more accurately diagnose the subtype of a patient's cancer, predict its behavior and help select precisely targeted therapy

Dr. George Demetri on blood test for cancer mutations
In this video Dana-Farber's George Demetri, MD, explains how a blood test can provide fuller picture of cancer mutations in gastrointestinal stromal tumors (GIST) than biopsy.

Groundbreaking Work in Cancer Chemical Biology Aims to Find New Cancer Treatments
James Bradner, MD, Medical Oncologist, describes what it takes to assemble the building blocks in research that lead to cures for cancer. This brief talk to donors at Dana-Farber's Joint Visiting Committee Symposium gives a glimpse into his research in cancer chemical biology, which is helping Dana-Farber pave the way to a world without cancer.

Immunology’s Role in the Fight Against Cancer
Kai W. Wucherpfennig, MD, PhD, Co-chair of the Department of Immunology and AIDS at Dana-Farber, describes how immunology research contributes to the fight against cancer and the development of new and promising cancer treatments for patients.

Jeff’s Story
Jeff was diagnosed with advanced lung cancer that had spread to his brain. His tumor tested positive for the ALK gene translocation so his treatment changed from chemotherapy to a targeted therapy that was more effective and had fewer side effects. Four years later, Jeff is still doing well.

Les’s Story

Les was diagnosed with GIST more than 20 years ago. After several surgeries, his cancer returned and surgery was no longer an option. Les entered a clinical trial for a targeted therapy and after 14 years on the now-FDA approved drug, he continues to enjoy his grandchildren and fishing. 


On the brink of discovery
Edward Benz, President and Chief Executive at Dana-Farber Cancer Institute, speaks about precision cancer medicine at the TEDx UMass Boston "Lighting the Way for the Future"

Precision Medicine Is Decoding the Mysteries of Cancer
Levi Garraway, MD, PhD, Director, Center for Cancer Precision Medicine at Dana-Farber Cancer Institute spoke about Dana-Farber’s groundbreaking work in precision medicine in this brief talk at the November 2014 SIDTALKS - Science, Innovation, and Discovey at Dana-Farber.

Profile: Moving the Science of Cancer Genetic Research and Treatment
The Profile research study is creating one of the largest databases of genetic abnormalities in cancer. More than 5,000 tumor samples have been genetically sequenced and the results are beginning to shed more light on just what makes certain cancers tick. In this video, scientists show how genetic testing in cancer happens - from tumor sample collection to data analysis - and talk about the promise that the technology holds for cancer research and care.

Rapid Heme Panel
The Rapid Heme Panel was developed by cancer specialists at Dana-Farber Cancer Institute and at Brigham and Women's Hospital. Jon Aster, MD, PhD discusses the new DNA-based test which relies on relatively new technology that analyzes the 95 genes which are among the most commonly mutated genes in blood cancers such as acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms.

Targeted therapy for lung cancer
Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene (ALK) are likely to fare better if treated with the targeted therapy (crizotinib) than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.